Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XERS shares. View XERS analyst ratings or view top-rated stocks .

What is Xeris Biopharma's stock price target for 2024?

4 brokers have issued 1-year target prices for Xeris Biopharma's shares. Their XERS share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 177.0% from the stock's current price. View analysts price targets for XERS or view top-rated stocks among Wall Street analysts .

How have XERS shares performed in 2024?

Xeris Biopharma's stock was trading at $2.35 on January 1st, 2024. Since then, XERS shares have decreased by 25.1% and is now trading at $1.76. View the best growth stocks for 2024 here .

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XERS earnings forecast .

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The business earned $44.39 million during the quarter, compared to the consensus estimate of $45.50 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 610.76% and a negative net margin of 37.98%. During the same period in the previous year, the company earned ($0.10) EPS.

What ETFs hold Xeris Biopharma's stock?

ETFs with the largest weight of Xeris Biopharma (NASDAQ:XERS) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.0 million-$200.0 million, compared to the consensus revenue estimate of $188.0 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Miragen Therapeutics (MGEN) , Novan (NOVN) , Dynavax Technologies (DVAX) , Zosano Pharma (ZSAN) , Cogent Biosciences (UMRX) and Organigram (OGI) .

When did Xeris Biopharma IPO?

Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.13%) and Deltec Asset Management LLC (0.04%). Insiders that own company stock include Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski. View institutional ownership trends .

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XERS

Xeris Biopharma (XERS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free XERS Stock Alerts

$1.76

-0.02 (-1.12%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.73
▼
$1.80
50-Day Range: $1.78
▼
$3.22
52-Week Range: $1.46
▼
$3.26

Volume: 1.09 million shs
Average Volume: 2.19 million shs
Market Capitalization: $247.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.88

Get Xeris Biopharma alerts:

Xeris Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 177.0% Upside
$4.88 Price Target
Short Interest: Bearish
6.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.57
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$9,720 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.38) to ($0.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

267th out of 918 stocks

Pharmaceutical Preparations Industry

105th out of 405 stocks

3.5

Analyst's Opinion

Consensus Rating
Xeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Xeris Biopharma has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.39% of the outstanding shares of Xeris Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Xeris Biopharma has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Xeris Biopharma has recently decreased by 2.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Xeris Biopharma does not currently pay a dividend.
Dividend Growth
Xeris Biopharma does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Xeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Xeris Biopharma is -1.57.

0.0

News and Social Media Coverage

Search Interest
Only 5 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,720.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.36% of the stock of Xeris Biopharma is held by insiders.
Percentage Held by Institutions
42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Xeris Biopharma are expected to grow in the coming year, from ($0.38) to ($0.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xeris Biopharma is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xeris Biopharma is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Xeris Biopharma Stock (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

XERS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XERS Stock News Headlines

April 5, 2024 | finance.yahoo.com

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions

April 3, 2024 | finance.yahoo.com

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 2, 2024 | finance.yahoo.com

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 18, 2024 | proactiveinvestors.com

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growth

March 9, 2024 | finance.yahoo.com

Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results

March 8, 2024 | seekingalpha.com

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 7, 2024 | insidermonkey.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Q4 2023 Xeris Biopharma Holdings Inc Earnings Call

March 6, 2024 | marketwatch.com

Xeris Biopharma Shares Drop After Weak 4Q Results

March 6, 2024 | msn.com

Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M

March 6, 2024 | investorplace.com

XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023

March 6, 2024 | proactiveinvestors.com

Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump

March 6, 2024 | businesswire.com

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

March 6, 2024 | businesswire.com

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

February 28, 2024 | businesswire.com

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 23, 2024 | theglobeandmail.com

3 Breakout Stocks Under $5 to Buy for More Upside

February 5, 2024 | finance.yahoo.com

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

February 3, 2024 | realmoney.thestreet.com

Big Game or Small, Here's How to Go About Stalking a Trade

January 10, 2024 | marketwatch.com

Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment

January 10, 2024 | marketwatch.com

Xeris Biopharma Shares Climb 12% on Amgen License Agreement

January 10, 2024 | msn.com

Why Is Xeris Biopharma (XERS) Stock Up 12% Today?

January 9, 2024 | seekingalpha.com

Xeris Biopharma: Speculative Buy, Size Your Position Accordingly

January 4, 2024 | marketwatch.com

Xeris Biopharma Holdings Shares Jump 14% on Raised 2023 Outlook

January 4, 2024 | msn.com

Xeris Biopharma sees FY revenue at higher end of guidance

See More Headlines

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XERS
CUSIP: N/A
CIK: 1867096
Web: www.xerispharma.com
Phone: (844) 445-5704
Fax: N/A
Employees: 377
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.88
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +175.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,260,000.00
Net Margins: -37.98%
Pretax Margin: -38.74%
Return on Equity: -610.76%
Return on Assets: -19.15%

Debt

Debt-to-Equity Ratio: 49.27
Current Ratio: 1.64
Quick Ratio: 1.23

Sales & Book Value

Annual Sales: $163.91 million
Price / Sales: 1.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -35.40

Miscellaneous

Outstanding Shares: 140,450,000
Free Float: 134,329,000
Market Cap: $248.60 million
Optionable: Optionable
Beta: 2.33

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Paul R. Edick (Age 68)
Chairman & CEO
Comp: $1.12M
Mr. John P. Shannon (Age 62)
President & COO
Comp: $827.72k
Ms. Beth P. Hecht J.D. (Age 60)
Chief Legal Officer & Corporate Secretary
Comp: $638.31k
Mr. Steven M. Pieper (Age 47)
Chief Financial Officer
Ms. Allison Wey
Senior Vice President of Investor Relations & Corporate Communications
Dr. Kenneth E. Johnson Pharm. D. (Age 61)
Pharm.D., Senior VP of Global Development & Medical Affairs
Mr. Kevin McCulloch
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XERS Stock Analysis - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings or view top-rated stocks.
What is Xeris Biopharma's stock price target for 2024?: 4 brokers have issued 1-year target prices for Xeris Biopharma's shares. Their XERS share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 177.0% from the stock's current price.
View analysts price targets for XERS or view top-rated stocks among Wall Street analysts.
How have XERS shares performed in 2024?: Xeris Biopharma's stock was trading at $2.35 on January 1st, 2024. Since then, XERS shares have decreased by 25.1% and is now trading at $1.76.
View the best growth stocks for 2024 here.
When is Xeris Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XERS earnings forecast.
How were Xeris Biopharma's earnings last quarter?: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The business earned $44.39 million during the quarter, compared to the consensus estimate of $45.50 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 610.76% and a negative net margin of 37.98%. During the same period in the previous year, the company earned ($0.10) EPS.
What ETFs hold Xeris Biopharma's stock?: ETFs with the largest weight of Xeris Biopharma (NASDAQ:XERS) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Xeris Biopharma issued on next quarter's earnings?: Xeris Biopharma updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.0 million-$200.0 million, compared to the consensus revenue estimate of $188.0 million.
What other stocks do shareholders of Xeris Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).
When did Xeris Biopharma IPO?: Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.
Who are Xeris Biopharma's major shareholders?: Xeris Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.13%) and Deltec Asset Management LLC (0.04%). Insiders that own company stock include Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends.
How do I buy shares of Xeris Biopharma?: Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XERS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial